Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

CSL to pay $355M upfront to co-develop Alentis' kidney and liver drug

5 October 2026 · By · Wire by Fusion42

Published

5 October 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

Australia

◆ Source

Read at endpoints.news →

◆ Verified

Fusion42 · 5 October 2026 · Fusion42 review

Australian pharmaceutical company CSL is paying $355 million upfront to co-develop Alentis Therapeutics' anti-fibrosis drug for kidney and liver treatment, with potential future payments up to $1.2 billion.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.

◆ ◆ The Wire takeaway

CSL's significant investment in Alentis opens a clear opportunity this quarter for founders in anti-fibrosis biotech to seek partnership or licensing deals as big pharma pursues kidney and liver therapies aggressively.

◆ Coverage

2 sources · 5 Oct 2026

◆ Related on Wire

◆ Topics

Biotechbiotechpartnershipdrug-developmentlicensingpharma-deal